In the general population, risk of cardiovascular disease is inversely associated with HDL-cholesterol levels. However, a new post hoc analysis of data from the German Diabetes Dialysis study reports no correlation between HDL cholesterol and mortality among patients on dialysis-a phenomenon that the authors attribute to HDL dysfunction.
High levels of serum HDL cholesterol are generally thought to protect against cardiovascular disease. However, a recent post hoc analysis of data from 1,255 diabetic patients with end-stage renal disease (ESRD) found no significant difference in cardio vascular or overall mortality between subgroups categorized according to HDL-cholesterol levels. 1 Silbernagel et al. attributed the lack of salutary effects of high HDL-cholesterol levels in this study to ESRD-associated HDL dysfunction. Given the proinflammatory nature of uraemic HDL, and its impaired capacity to participate in reverse cholesterol transport, the finding that high levels of dys functional HDL do not confer benefit in patients with ESRD is not surprising.
Chronic kidney disease (CKD) results in substantial changes to the serum concentrations of lipids and the composition and function of lipoproteins. 2 In addition, comorbid conditions, renal replacement modalities (haemodialysis, peritoneal dialysis and renal transplantation), drug regimens and preexisting genetic disorders of lipid metabolism modulate serum lipid and lipoprotein profiles in the CKD population. In patients on haemodialysis, levels of serum cholesterol and LDL cholesterol are generally within or below the normal limits, serum HDLcholesterol levels are commonly reduced, and levels of serum triglycerides and VLDL are elevated. These changes are accompanied by an accumulation of highly atherogenic and proinflammatory intermediate density lipoprotein (IDL), small dense LDL, chylomicron remnants and oxidized LDL.
HDL abnormalities in patients on dialysis generally include reduced levels of serum apolipoprotein A-I (apoA-I), apolipoprotein A-II (apoA-II), HDL cholesterol and HDL phospholipids, and elevated levels of HDL-triglycerides. Maturation of cholesterol ester (CE)-poor HDL3 to CE-rich HDL2 is impaired, and HDL antioxidant, anti-inflammatory and reverse cholesterol transport properties are defective in the ESRD population. [3] [4] [5] Abnormalities of HDL structure and function in advanced CKD are mediated by a reduction in the serum levels of apoA-I and apoA-II (owing to reduced biosynthesis and increased catabolism), deficiency of lecithin cholesterol acyltransferase (LCAT, which is essential for esterification of free cholesterol on the surface of HDL and the formation of CE-rich HDL), upregulation of acyl c oenzyme A:cholesterol acyltransferase 1 and 2 (ACAT-1 and 2, which promote esterification and retention of intracellular cholesterol), oxidative modification of HDL 3, 4 (which lowers its affinity for binding to ATPbinding cassette sub-family A member 1 [ABCA1] and ATP-binding cassette subfamily G member 1, the gateways of cholesterol efflux), 6 a reduction in the levels of the key HDL-associated antioxidant enzymes, serum paraoxonase/arylesterase 1 and glutathione peroxidase 1, 4,5 and the presence of highly proinflammatory serum amyloid A protein (SAA) in the HDL of patients on haemodialysis. 7 Hypoalbuminaemia (caused by systemic inflammation and malnutrition, which are fairly common in patients with ESRD) also contributes to reduced HDL-cholesterol levels by limiting receptorindependent transfer of albumin-bound chol esterol to HDL in the blood stream. These abnormalities work in concert to lower HDL levels and impair HDL maturation as well as its antioxidant, anti-inflammatory and reverse cholesterol transport capacities. In patients on haemodialysis, the ability of HDL to remove cholesterol from lipid-laden macro phages, 8 reverse LDL oxidation and prevent monocyte attachment to, and infiltration of, the vascular endothelium 7 is greatly reduced. HDL from patients with ESRD can trigger the release of inflammatory cytokines by macrophages, 7, 8 a phenomenon that is partly attributable to the presence of SAA. 7 The mechanism that underlies the elevated serum HDL cholesterol levels in a subgroup of patients with ESRD in the study by Silbernagel et al., 1 and in other studies, to SRB1 and limit HDL binding (Figure 1) . Impairments of either CETP-mediated CE exchange for triglyceride with IDL and/or LDL or HDL binding to SRB1 can lead to substantial elevations of HDL cholesterol, which are associated with impaired reverse cholesterol transport and accumulation of IDL and small dense LDL particles. Such accumulation results in accelerated atherosclerosis and systemic inflammation. Thus contrary to common perception, high HDLcholesterol levels do not necessarily suggest favourable outcomes. In fact, Honda et al. showed that patients on haemodialysis who have high HDL cholesterol concentrations have high levels of oxidized HDL and increased cardiovascular mortality. 9 Likewise an analysis of data from 33,109 patients on chronic haemodialysis in US clinics by Moradi et al. revealed a U-shaped association between HDL cholesterol levels and allcause and cardiovascular mortality. 10 Patients with HDL cholesterol levels <0.78 mmol/l (30 mg/dl) or >1.55 mmol/l (60 mg/dl) exhibited significant increases in cardiovascular and all-cause mortality, whereas those with HDL cholesterol levels between 1.30 mmol/l (50 mg/dl) and 1.55 mmol/l had the highest survival.
The reasons for the differences between the results of the studies by Moradi et al. 10 and Honda et al., 9 which showed increased mortality in patients with high HDL levels, and the study by Silbernagel et al.,
1 which showed no difference in mortality between patients in different HDL quartile subgroups, are unclear. However, several factors might account for the apparent disparities. In the latter study, 1 all patients had diabetes mellitus, which has a significant impact on HDL structure, function and cardiovascular complications, and 50% were treated with statins, which alters cholesterol metabolism and LDL to HDL cholesterol ratio. The highest HDL quartile was 1.47 ± 0.25 mmol/l (56.9 ± 9.6 mg/dl), which encompasses many patients with levels below the 1.55 mmol/l threshold shown to be associated with increased mortality. Moreover, the percentage of women was substantially greater, and body mass index, levels of trigly cerides and C-reactive protein were lower in the highest HDL quartile than in the other quartiles. These differences might, in part, account for the high HDL levels in this subgroup. In addition, the number of patients included in the analysis by Sibernagel et al. 1 was far smaller than the number studied by Moradi et al., 10 which could have impacted the results of the statistical analysis. Finally differences in the ethnic backgrounds of the study populations and in environmental factors might have, in part, contributed to the apparent difference in results.
The lack of association between HDL chol esterol level and cardiovascular and all-cause mortality in patients with ESRD shown by Sibernagel et al. points to HDL dysfunction, which is primarily driven by systemic inflammation and oxidative stress. Identification of the underlying mechanisms and effective treatment of systemic inflammation and oxidative stress are the key steps in restoring HDL function and lowering the burden of cardiovascular and all-cause morbidity and mortality in the ESRD population. 
